How much funding has UROMEMS raised?

UROMEMS has raised $134.3M in total funding, most recently a Corporate Round.

Who are UROMEMS's investors?

UROMEMS's investors include Ajax Health, Crédit Mutuel Innovation, European Innovation Council Fund.

Where is UROMEMS headquartered?

UROMEMS is headquartered in Grenoble, France.

What industry is UROMEMS in?

UROMEMS operates in Biotech, Healthcare.

UROMEMS

Science behind it. Life ahead of it.

Grenoble, France · Founded 2011 · $134.3M raised

Biotech

Healthcare

Headquarters: Grenoble
Employees: 11–50
Founded: 2011
Business Model: B2B

Website: uromems.com
Total Funding: $134.3M
Last Round: $60.0M Corporate RoundMar 2025
Rounds: 4

About

UroMems is a global medtech company co-founded in 2011 by Professor Pierre Mozer, Hamid Lamraoui, and Stéphane Lavallée, developing UroActive — the first smart, automated artificial urinary sphincter (AUS) implant for the treatment of stress urinary incontinence in both women and men. The active implantable device leverages embedded systems and micro-technologies to remotely adjust to each patient's individual needs, improving quality of life without manual patient intervention. UroMems has completed first-in-human feasibility studies in both female and male patients and received FDA IDE approval in 2025 to advance pivotal clinical trials.

Summary

UROMEMS is a Biotech company based in Grenoble, France, founded in 2011. It has raised $134.3M in total across 4 rounds, most recently a $60.0M Corporate Round round in Mar 2025. Investors include Ajax Health, Crédit Mutuel Innovation and European Innovation Council Fund.